163 related articles for article (PubMed ID: 36116972)
1. Liver graft injury caused by de novo donor-specific HLA antibodies in pediatric liver transplant recipients with low, moderate, and high immunologic risk.
Liu W; Wang ZL; Kang ZY; Xiao YL; Liu C; Li DH
Am J Surg; 2023 Feb; 225(2):275-281. PubMed ID: 36116972
[TBL] [Abstract][Full Text] [Related]
2. De novo donor-specific HLA antibodies reduce graft survival rates and increase the risk of kidney transplant rejection: A single-center retrospective study.
Liu W; Zhao J; Kang ZY; Xiao YL; Yang L; Liu C; Li DH
Transpl Immunol; 2021 Oct; 68():101430. PubMed ID: 34147608
[TBL] [Abstract][Full Text] [Related]
3. Solid-Phase C1q/C3d Fixing Readouts Correlate with High Median Fluorescence Intensity (MFI) De Novo Donor-Specific HLA Antibodies and C4d⁺ Antibody-Mediated Rejection in Kidney Transplant Recipients.
Tatapudi VS; Kopchaliiska D; da Gente GJ; Buenaventura OF; Singh M; Laszik Z; Adey DB; Rajalingam R
Ann Transplant; 2021 Dec; 26():e934175. PubMed ID: 34848674
[TBL] [Abstract][Full Text] [Related]
4. Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients.
Comoli P; Cioni M; Tagliamacco A; Quartuccio G; Innocente A; Fontana I; Trivelli A; Magnasco A; Nocco A; Klersy C; Rubert L; Ramondetta M; Zecca M; Garibotto G; Ghiggeri GM; Cardillo M; Nocera A; Ginevri F
Am J Transplant; 2016 Jul; 16(7):2106-16. PubMed ID: 26725780
[TBL] [Abstract][Full Text] [Related]
5. Post-transplant de novo non donor-specific HLA antibodies are not associated with poor graft outcome in non-sensitized pediatric recipients of kidney transplantation.
Cioni M; Comoli P; Tagliamacco A; Innocente A; Basso S; Fontana I; Magnasco A; Trivelli A; Nocco A; Macchiagodena M; Catenacci L; Klersy C; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Nocera A
Transpl Immunol; 2021 Apr; 65():101375. PubMed ID: 33610675
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival.
Wiebe C; Gareau AJ; Pochinco D; Gibson IW; Ho J; Birk PE; Blydt-Hansen T; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
Am J Transplant; 2017 Mar; 17(3):703-711. PubMed ID: 27539748
[TBL] [Abstract][Full Text] [Related]
7. Renal transplant outcomes and de novo donor-specific anti-human leukocyte antigen antibodies: a systematic review.
Sharma A; Lewis JR; Lim WH; Palmer S; Strippoli G; Chapman JR; Alexander SI; Craig JC; Wong G
Nephrol Dial Transplant; 2018 Aug; 33(8):1472-1480. PubMed ID: 29660004
[TBL] [Abstract][Full Text] [Related]
8. Predictors of graft failure after first detection of de novo donor-specific HLA antibodies in kidney transplant recipients.
López Del Moral C; Wu K; Naik M; Osmanodja B; Akifova A; Lachmann N; Stauch D; Hergovits S; Choi M; Bachmann F; Halleck F; Schrezenmeier E; Schmidt D; Budde K
Nephrol Dial Transplant; 2023 Dec; 39(1):84-94. PubMed ID: 37410616
[TBL] [Abstract][Full Text] [Related]
9. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of a Steroid Avoidance Immunosuppression Regimen in Renal Transplant Patients With De Novo or Preformed Donor-Specific Antibodies: A Single-Center Study.
Schutt R; Case J; Kurian SM; Spierling Bagsic SR; Barrick BL; Toll AE; Zhang Q; Reed EF; Quigley MM; Schaffer R; Fisher JS; Rice JC; Marsh CL
Transplant Proc; 2021 Apr; 53(3):950-961. PubMed ID: 33293041
[TBL] [Abstract][Full Text] [Related]
12. De Novo Donor-Specific Human Leukocyte Antigen Antibodies in Nonsensitized Kidney Transplant Recipients After T Cell-Mediated Rejection.
Chemouny JM; Suberbielle C; Rabant M; Zuber J; Alyanakian MA; Lebreton X; Carmagnat M; Pinheiro N; Loupy A; Van Huyen JP; Timsit MO; Charron D; Legendre C; Anglicheau D
Transplantation; 2015 May; 99(5):965-72. PubMed ID: 25340597
[TBL] [Abstract][Full Text] [Related]
13. Impact of calcineurin inhibitor-free immunosuppression on de novo donor-specific antibody formation in liver transplant recipients.
Meszaros M; Dubois V; Congy-Jolivet N; Hamada S; Thevenin C; Faure S; Boillot O; Kamar N; Pageaux GP; Del Bello A; Dumortier J
Liver Int; 2022 May; 42(5):1132-1143. PubMed ID: 35184373
[TBL] [Abstract][Full Text] [Related]
14. Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss.
Nocera A; Tagliamacco A; Cioni M; Innocente A; Fontana I; Barbano G; Carrea A; Ramondetta M; Sementa A; Basso S; Quartuccio G; Klersy C; Bertocchi M; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Comoli P; Ginevri F
Am J Transplant; 2017 Mar; 17(3):692-702. PubMed ID: 27501275
[TBL] [Abstract][Full Text] [Related]
15. De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients.
Cioni M; Nocera A; Innocente A; Tagliamacco A; Trivelli A; Basso S; Quartuccio G; Fontana I; Magnasco A; Drago F; Gurrado A; Guido I; Compagno F; Garibotto G; Klersy C; Verrina E; Ghiggeri GM; Cardillo M; Comoli P; Ginevri F
J Immunol Res; 2017; 2017():1747030. PubMed ID: 28367453
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
[TBL] [Abstract][Full Text] [Related]
17. Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies.
Steggerda JA; Kim IK; Haas M; Zhang X; Kang A; Pizzo H; Kamil E; Jordan S; Puliyanda D
Pediatr Transplant; 2017 Dec; 21(8):. PubMed ID: 29159992
[TBL] [Abstract][Full Text] [Related]
18. Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation.
Vo AA; Aubert O; Haas M; Huang E; Zhang X; Choi J; Peng A; Najjar R; Sethi S; Ammerman N; Lim K; Jordan SC
Transplantation; 2019 Dec; 103(12):2666-2674. PubMed ID: 30883456
[TBL] [Abstract][Full Text] [Related]
19. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.
Schinstock CA; Cosio F; Cheungpasitporn W; Dadhania DM; Everly MJ; Samaniego-Picota MD; Cornell L; Stegall MD
Am J Transplant; 2017 Jun; 17(6):1574-1584. PubMed ID: 27977905
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
